Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Turmeric compound tested as vaginal treatment for cervical precancer

NCT ID NCT04266275

Disease control Sponsor: Lisa Flowers Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether curcumin, the active compound in turmeric, can clear HPV and prevent precancerous cervical lesions from returning. About 200 women with low-grade or recently treated high-grade cervical precancer will insert curcumin or placebo capsules vaginally once a week for 20 weeks. After 6 months, they will have a Pap smear and HPV test to see if curcumin helps clear the virus.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
curcumin (from turmeric) vaginal capsules
What this could lead to
If it works, this could offer a low-cost, low-toxicity option to help clear HPV and prevent cervical precancer from coming back.
What could go wrong
This is an early phase 2 trial with only 200 participants. Curcumin is poorly absorbed, and the vaginal route may not work well. The study is not yet recruiting, so results are years away.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2027

An estimate. Start dates often move.

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * HIV-uninfected and infected women (without current AIDS-defining illness) * Presence of a cervix * Biopsy-proven LSIL disease or recently treated HSIL disease * Adherence to combined anti-retrovirals (cART) if HIV infected * On continuous antiretrovirals with a cluster of differentiation 4 (CD4) count \>200 cells/ml with sustained undetectable viral load for at least 3 months (only for HIV-positive participants) * On reliable birth control: combined oral contraceptive pills (OCP), long-acting reversible contraception (LARC), bilateral tubal ligation (BTL) or Depo-Provera (birth control shot) * Willing to conform to the study requirements * Reliable follow-up and contact information * No risk factors for HSIL or microinvasive disease (no colposcopic features of microinvasion, adequate colposcopy and negative endocervical curettage) * For women with HSIL only, LEEP completed within 6 weeks preceding initial encounter with study staff and adequate wound healing Exclusion Criteria: * Untreated HSIL or invasive features on colposcopy and the biopsy specimen * Not adherent to anti-retroviral therapy (cART) (HIV infected participants) * CD4 count =\<200 cells/ml and detectable viral load within the last 3 months (only for HIV-positive participants) * Lactating and pregnant people * Patient with irregular cycles (more than once a month) * Not on reliable birth control. * Previous hysterectomy * Prior diagnosis of cervical cancer, treated or untreated * Inability to provide informed consent * Medical condition that interferes with the conduct of the study in the investigator's opinion * Evidence of active cervical infection or serious cervical disease necessitating surgery * Known bleeding diathesis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical intraepithelial neoplasia grade 1 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cervical intraepithelial neoplasia cervical intraepithelial neoplasia grade 2/3 infectious disease neoplasm Uterine Cervical Neoplasms uterine cervix carcinoma in situ uterine cervix neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neoplasm cervix

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Emory University

    Atlanta, Georgia, 30303, United States

  • Grady Hospital - Ponce De Leon Clinic

    Atlanta, Georgia, 30308, United States

  • Grady Memorial Hospital

    Atlanta, Georgia, 30303, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.